Eli Lilly reported a strong Q1 2026 with 55.55% revenue growth to $19.8 billion, driven by blockbuster drugs Mounjaro and Zepbound, and raised its full-year revenue guidance. The company is investing aggressively in AI drug discovery and acquisitions, signaling growth momentum. Pfizer, meanwhile, posted a 1.2% revenue decline in Q4 2025, still recovering from COVID-related revenue drops, with growth in non-COVID products but steep declines in vaccines and treatments like Comirnaty and Paxlovid. Pfizer’s M&A strategy focuses on replacing lost revenue, while Lilly’s approach compounds future growth. For long-term investors, Lilly appears stronger despite a higher valuation, while Pfizer offers a higher dividend yield but faces patent cliff challenges.
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU, an oral PROTAC drug for advanced breast cancer. The FDA recently approved VEPPANU for estrogen receptor-positive, ...
Pfizer is currently trading at a low forward earnings multiple of 9.1x and offers a compelling 6.7% dividend yield, making it materially undervalued. The company is facing fewer losses from patent expirations than previously expected, with management...
Nvidia's market capitalization recently exceeded $5.3 trillion, surpassing the combined value of all 59 healthcare companies in the S&P 500, which total about $5.2 trillion. This shift highlights the massive investor confidence in AI infrastructure, ...
Warren Buffett's investment approach focuses on buying durable, cash-generating companies at reasonable prices, with several current Berkshire Hathaway holdings trading below $30. Stocks like Kraft Heinz, Sirius XM, and Liberty Latin America fit this...
Arvinas and Pfizer have entered a licensing deal with Rigel Pharmaceuticals granting Rigel exclusive global rights to develop, manufacture, and commercialize VEPPANU, the first FDA-approved PROTAC drug for certain advanced breast cancers. The deal in...
